Free Trial
→ New Rule Hits in July — The Smart Money Already Moved (From American Alternative) (Ad)
NASDAQ:BNTC

Benitec Biopharma 5/14/2025 Earnings Report

Benitec Biopharma logo
$13.36 -1.61 (-10.72%)
As of 02:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Benitec Biopharma EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Benitec Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Benitec Biopharma Announcement Details

Quarter
Date
5/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Benitec Biopharma Earnings Headlines

Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer
April 16, 2025 | seekingalpha.com
Benitec Biopharma price target raised to $20 from $18 at Citizens JMP
April 12, 2025 | markets.businessinsider.com
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
June 25, 2025 | American Alternative (Ad)
Benitec Biopharma participates in a conference call with Cantor Fitzgerald
April 8, 2025 | markets.businessinsider.com
Insiders Are Loving These 5 Tech and Biotech Stocks
April 2, 2025 | 247wallst.com
Benitec Biopharma completes stock and warrant offerings
March 30, 2025 | investing.com
See More Benitec Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email.

About Benitec Biopharma

Benitec Biopharma (NASDAQ:BNTC) Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

View Benitec Biopharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles